Arie S Belldegrun MD

Chief of the Division of Urologic Oncology and Director of Urologic Research in the Department of Urology at the University of California, Los Angeles. He is a UCLA Professor of Urology, Clinical Director of the UCLA Prostate Disease Research Program and Surgical Director of the UCLA Kidney Cancer Program. He is also the Founder and Chairman of the Board of Agensys, Inc

Join to view full profile

200 Medical PlzSte 140Los Angeles, CA 90095
Phone+1 310-794-7700
Fax+1 310-301-8751

Dr. Belldegrun is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Belldegrun's full profile Already have an account?

Education & Training

University of California (Irvine)Residency, Urology, 2022 - 2027
Clinical Center at the National Institutes of HealthResidency, Urology, 1987 - 1988
Clinical Center at the National Institutes of HealthResidency, Surgery, 1985 - 1987
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1982 - 1985
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1975

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1988 - 2027
NY State Medical License 1987 - 2026
MA State Medical License 1983 - 2003
VA State Medical License 1985 - 2000

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
America's Top Doctors Castle Connolly, 2009-2014

Clinical Trials

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
TERMINATED
PHASE2
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
COMPLETED
PHASE1
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

Oncologist, Business Leader, and Investor Arie S. Belldegrun Discusses a Career in Innovative Medical Entrepreneurship: A Conversation with Ken Herrmann and Johannes C...
Arie S Belldegrun, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine. 2024-12-03
Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.
Cedric Lebacle, Aydin Pooli, Brian Shuch, Nagesh Rao, Karim Chamie
Cancer Investigation. 2024-01-01
17 citations
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC...
Izak Faiena, Begoña Comin-Anduix, Beata Berent-Maoz, Adrian Bot, Nazy Zomorodian
Journal of Immunotherapy. 2020-11-01

Press Mentions

New Imaging Technique Accurately Detects Aggressive Kidney Cancer, Claims StudyOctober 21st, 2024
Billionaire Surgeon Donates $120M to UCLAAugust 28th, 2024
Local Companies and Research Institutes at Forefront of Cancer Immunotherapy DevelopmentMarch 13th, 2023